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Identification of a Small Molecule that Inhibits
Herpes Simplex Virus DNA Polymerase Subunit
Interactions and Viral Replication
and sight-threatening ocular infections [3]. In newborns
and immunosuppressed individuals such as patients
with AIDS, HSV infections are even more severe. Safe,
effective antivirals against HSV, notably the nucleoside
analog acyclovir (ACV) whose triphosphate inhibits the
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Boston, Massachusetts 02115 viral polymerase, have been developed and are widely
used. However, ACV is not highly potent (active at M
concentrations), and there are HSV infections for which
it is not particularly efficacious. Moreover, ACV-resis-Summary
tance is a problem, especially in the immunosuppressed
[4, 5]. For these and other reasons, it would be desirableThe interaction between the catalytic subunit Pol and
to develop safe, effective anti-HSV agents with mecha-the processivity subunit UL42 of herpes simplex virus
nisms different from that of ACV. Interestingly, nearly allDNA polymerase has been characterized structurally
ACV-resistance pol mutations map in regions encodingand mutationally and is a potential target for novel
motifs that are conserved with human cellular DNA poly-antiviral drugs. We developed and validated an assay
merases (reviewed in [6]). Thus, ACV appears to exploitfor small molecules that could disrupt the interaction
only rather subtle differences between viral and cellularof UL42 and a Pol-derived peptide and used it to screen
polymerases.16,000 compounds. Of 37 “hits” identified, four inhib-
In contrast, the interaction between Pol and UL42ited UL42-stimulated long-chain DNA synthesis by Pol
is much more distinct, with no detectable sequencein vitro, of which two exhibited little inhibition of poly-
homology between the Pol C terminus, which interactsmerase activity by Pol alone. One of these specifically
with UL42, and cellular or even other herpesvirus poly-inhibited the physical interaction of Pol and UL42 and
merases. Several lines of evidence indicate that thisalso inhibited viral replication at concentrations below
interaction is required for viral replication. In vitro, UL42those that caused cytotoxic effects. Thus, a small mol-
is not required for catalysis by Pol but is necessary forecule can inhibit this protein-protein interaction, which
long-chain DNA synthesis [7]. Moreover, mutants of Polprovides a starting point for the discovery of new anti-
or UL42 that are specifically impaired for subunit interac-viral drugs.
tions exhibit drastic defects in long-chain DNA synthesis
in vitro and are unable to complement the replication
Introduction
of their corresponding null mutant viruses in cells [8–10].
Peptides corresponding to the extreme C terminus of
Protein-protein interactions are crucial to most, if not all,
Pol, which is both necessary and sufficient for interac-
biological processes. Because these interactions also
tion with UL42 [8, 9, 11–13], can inhibit long-chain DNAoften determine specificity, selective disruption of these
synthesis mediated by UL42 [11, 14, 15]. One such pep-interactions should, in principle, be an excellent strategy
tide, when fused to E. coli enterotoxin B, inhibits HSVfor drug discovery. However, there are only a few exam-
replication in cell culture [16]. Thus, the Pol-UL42 inter-ples of small molecules that disrupt protein-protein in-
action appears to be a valid target for new anti-HSVteractions and exert effects inside cells (reviewed in [1,
drugs.2]). The paucity of such compounds derives in part from
The crystal structure of UL42 bound to the C-terminala reluctance to target protein-protein interactions for
36 residues of Pol has been elucidated to 2.7 A˚ [17].drug development based on the perception that these
The interaction entails a fairly large interface (1087 A˚2interactions entail large, flat interfaces that cannot be
of the peptide). However, a peptide corresponding toreadily disrupted by small molecules. Although this per-
the C-terminal 18 residues binds with similar affinityception may be accurate in a number of cases, there are
(Kd  1–2 M), as does one corresponding to theimportant counterexamples that emphasize the value of
C-terminal 36 residues [8]. Moreover, mutational analy-structural and mutational analyses in choosing protein-
ses of particular Pol and UL42 residues that participateprotein interactions to target for drug discovery [1, 2].
in hydrogen-bonding interactions have shown that eachThe interaction between the two subunits of herpes
of these residues is crucial for the interaction [8]. Assimplex virus (HSV) type 1 DNA polymerase, the catalytic
interruption of a few hydrogen bonds is sufficient tosubunit UL30 (Pol) and the processivity subunit UL42,
disrupt the Pol-UL42 interaction, it seemed possible thathas been characterized structurally and mutationally [8,
a small molecule might be able to do the same. We14, 17] and may represent a target for new anti-HSV
therefore developed and validated a high-throughputdrugs. In immunocompetent adults, HSV causes a spec-
screen for compounds that could disrupt polymerasetrum of diseases including debilitating genital infections
subunit interactions and applied it to a library of small
molecules. Among these, we have identified a molecule*Correspondence: don_coen@hms.harvard.edu
that specifically inhibits Pol-UL42 interactions and has1Present address: Gru¨nenthal Pharma AG, Im Sa¨ndli, 8756 Mitlo¨di,
Switzerland. antiviral activity.
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Figure 1. Validation of the FP Assay
(A) Varying concentrations of MBP-UL42 (UL42wt, solid line) or a mutant MBP-UL42 that does not bind to HSV Pol (UL42-I160, dotted line)
were added to 1 nM of a fluorescently labeled peptide corresponding to the C-terminal 18 residues of Pol, and FP was measured.
(B) Varying concentrations of unlableled peptide A, which corresponds to the C-terminal 36 residues of Pol, were titrated into reactions
containing 7 M UL42 and 1 nM labeled peptide, and FP was measured. The percent of inhibition of FP relative to no peptide A (0%) and
free peptide (100%) is plotted versus the concentration of peptide A.
Results and Discussion peptide determined previously in our laboratory by using
isothermal calorimetry [8]. (When more highly purified
MBP-UL42 was used in the FP assay, the Kd value was,Development and Validation of an Assay
to Identify Small Molecule Inhibitors indeed, 2 M [C.C., A. Loregian, and D.M.C., unpub-
lished data].) Thus, this assay could specifically andof the Pol-UL42 Interaction
We developed an assay for the Pol-UL42 interaction quantitatively measure interactions between UL42 and
the Pol-derived peptide.based on fluorescence polarization (FP), a format that
facilitates high-throughput screening [18, 19]. In this We next investigated whether this assay could detect
a known inhibitor of Pol-UL42 interactions—a peptideassay, a peptide corresponding to the C-terminal 18
residues of Pol, which was labeled with the fluorophore corresponding to the last 36 residues of Pol (peptide A)
that has been shown to inhibit long-chain DNA synthesisOregon Green, was mixed with UL42 fused to maltose
binding protein (MBP-UL42), a fusion protein that retains by Pol and UL42 [14, 15]. A binding reaction of 7 M
MBP-UL42 and 1 nM labeled peptide was titrated withall known biochemical activities of UL42 [10, 21, 23]. The
free-labeled peptide tumbles relatively rapidly. Thus, if increasing concentrations of unlabeled peptide A (Fig-
ure 1B). FP from the UL42-peptide interaction was inhib-it is excited with polarized light, its polarization is low
by the time emission occurs. However, upon binding to ited by peptide A with a 50% inhibitory concentration
(IC50) of 6 M. This value is similar to that observed forMBP-UL42, the peptide would be expected to tumble
much more slowly, so the light emitted would remain inhibition of long-chain DNA synthesis by this peptide
[14, 15]. An unlabeled peptide corresponding to the Crelatively polarized, resulting in an increase in FP.
Titration of MBP-UL42 into a solution of 1 nM labeled terminus of HCMV Pol [22] did not inhibit FP from the
UL42-peptide interaction, even at concentrations aspeptide resulted in two phases of increasing FP, with
steeper increases at lower concentrations, followed by high as 50 M (data not shown). Thus, this assay could
detect specific inhibition of interactions between UL42shallower increases at higher concentrations (Figure
1A). (These shallower increases were essentially elimi- and the Pol-derived peptide.
nated when more highly purified MBP-UL42 was used
[C.C., A. Loregian, and D.M.C., unpublished data]; how- High-Throughput Screen
We then used the FP assay to screen a library of 16,320ever, purifying to this extent decreased the yield of pro-
tein so that it became difficult to use the assay for high- compounds, each at a concentration of 10 g/ml. Our
initial criterion for an active compound was one thatthroughput screening.) MBP-UL42 did not result in
increasing FP with a labeled peptide derived from the resulted in an FP value of3 standard deviations below
the mean FP for all the compounds. 98 compoundsC terminus of human cytomegalovirus (HCMV) Pol (C.C.,
A. Loregian, and D.M.C., unpublished data). As a control, (0.6% of the compounds screened) met this criterion.
Of these, however, 61 turned out to be false positiveswe also titrated a mutant MBP-UL42 (I-160), which is
severely impaired for binding to Pol and Pol-derived due to, for example, intrinsic fluorescence of the small
molecule. Thus, the screen identified 37 hits to pursuepeptides [8, 10]. This resulted in only the shallow increases
in FP seen at high concentrations with the wild-type (0.2% of library).
Of the 37 hits, we identified nine (0.06%) that were theprotein, which we infer are due to nonspecific binding.
Analysis of the data in Figure 1A, including subtraction most promising based on their reproducible inhibition of
FP (Figure 2). These fell into six structural classes ofof the nonspecific component, revealed a Kd value of
5 M for the interaction between MBP-UL42 and the which three have two members each (BP2 and BP7,
BP3 and BP9, and BP6 and BP8), and three have onepeptide. This value is close to that (2 M) for MBP-
UL42 and the corresponding unlabeled 18 residue Pol member each (BP1, BP4, and BP5). BP1 and BP5 each
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Figure 2. Chemical Structures of Nine Hits from Screen for Inhibitors of UL42-Pol Peptide Interactions
The compounds are designated as BP1–BP9.
contain a peptide bond. None of these molecules was Specific Inhibition of Long-Chain DNA Synthesis
Mediated by UL42identical to any from the same library that were most
potent for inhibition of a different protein-protein interac- We next tested the nine compounds for the ability to
interfere with Pol-UL42 interactions in a functionaltion, that of Bak BH3-Bcl-xL [20]. Interestingly, BP3 and
BP9 are similar to one class of these Bak BH3-Bcl-xL assay—UL42-dependent long-chain DNA synthesis by
Pol (Figure 4). In this assay, which utilizes a poly(dA)inhibitors but differ in the number of halogens, while
BP5 resembles a second class of Bak Bak BH3-Bcl-xL template and oligo(dT) primers [21], Pol alone adds only
one or a few bases (lane 1), while Pol plus UL42 addsinhibitors but is distinct in terms of the orientation of
the peptide bond and in containing a thiadiazol in the many bases, leading to incorporation into longer prod-
ucts that can be visualized following alkaline agaroseplace of a phenyl. Thus, the screen identified a small
number of distinct inhibitors. gel electrophoresis (lane 2). As previously observed [14,
15], peptide A inhibited long-chain DNA synthesis (lanes
3 and 4). We initially tested each compound from theDose Dependence of Inhibition
For further studies, the nine compounds and a Bak BH3- screen at 30 M. At this concentration, BP1 (lane 5)
and BP3 (lane 7) severely decreased long-chain DNABcl-xL inhibitor that resembles BP5 (BH3I-2, [20]) were
reordered from the supplier and subjected to mass synthesis. This concentration of BP5 (lane 9) and BP9
(not shown) also markedly decreased long-chain DNAspectroscopy (MS) analysis. Although impurities were
detected, the expected peak predominated for each synthesis. BP4 exhibited more modest inhibition. BP2,
BP6, BP7, and BP8 (lanes 6, 10, 11, and 12) exertedcompound (see Supplemental Data for MS and high-
performance liquid chromatography plots for BP5). In even less inhibition of long-chain DNA synthesis, consis-
tent with their lack of dose-dependent inhibition of FP.an initial study, we performed dose-response analyses
of the inhibition of FP from the UL42-Pol peptide interac- It is possible that these hydrophobic compounds scored
as hits in the high-throughput assay due to an effecttion for each of the nine compounds in Figure 2. Of
these, five compounds—BP1, BP3, BP4, BP5, and on the fluorophore rather than on the protein-peptide
interaction.BP9—reproducibly exhibited a dose-dependent reduc-
tion in FP, with IC50 values between 10 and 40M (Figure To quantify the effects of the four most active com-
pounds (BP1, 3, 5, and 9), different doses of the active3 and Table 1). Two structurally related pairs of com-
pounds (BP2 and BP7, and BP6 and BP8) did not repro- compounds were tested for their effects on long-chain
DNA synthesis, as illustrated here only for BP9 (Figureducibly inhibit FP in a dose-dependent manner (not
shown). BH3I-2 did not detectably reduce FP at concen- 4, lanes 13–17). These data were quantified by phos-
phorimage analysis, as described [14], or by the bindingtrations as high as 40 M (Figure 3; lack of solubility
precluded testing higher concentrations). of radiolabeled products to DEAE filters. Both assays
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Figure 3. Dose-Dependence of Inhibition of FP
Varying concentrations of BP1 (filled dia-
monds), BP3 (squares), BP4 (triangles), BP5
(filled circles), BP9 (open squares), and BH3I-2
(open circles) were titrated into reactions
containing 7 M UL42 and 1 nM labeled pep-
tide, and FP was measured. The values are
plotted relative to the amount of signal with
no compound added (100% peptide bound)
and no UL42 (0% peptide bound) versus the
concentration of the compounds.
yielded similar results. The IC50s of the active com- the MBP fusion partner (Figure 5A, lane 1). Radiolabeled
Pol alone did not bind to an amylose column (lane 6)pounds for inhibition of long-chain DNA synthesis were
all 30 M (Table 1). nor to a glutathione-S-transferase fusion to the human
cytomegalovirus (HCMV) homolog of HSV UL42, UL44The inhibition of long-chain DNA synthesis could be
due to effects on the catalytic activity of the Pol subunit (lane 14), as previously observed [22]. Moreover, the
catalytic subunit of HCMV DNA polymerase, UL54, didrather than effects on a UL42-mediated activity. We
therefore tested varying concentrations of the four ac- not bind to MBP-UL42 (lane 7), although, as reported
[22], it did bind to UL44 (lane 8). Thus, the interactiontive compounds on DNA synthesis by Pol alone by using
a filter binding assay. As summarized in Table 1, the of HSV Pol with UL42 in this assay is specific.
Unfortunately, we were unable to study BP1 by usingstructurally related compounds BP3 and BP9 inhibited
the activity of Pol alone, at least as potently as they this assay or cell-culture-based assays (see below) due
to its lack of solubility under the conditions of theseinhibited long-chain DNA synthesis mediated by UL42.
Thus, inhibition by these two compounds was not spe- assays. However, BP5 retained solubility under these
conditions. BP5 inhibited the Pol-UL42 interaction in acific for UL42-mediated activity. However, BP1 and BP5,
both of which share peptide-like features, inhibited ac- dose-dependent manner, with an IC50 of about 4 M
(Figure 5A, lanes 1-5, and Figure 5B). However, it hadtivity of Pol alone much less potently (Table 1), indicating
a specific effect on UL42-mediated long-chain DNA syn- little or no effect on the interaction of HCMV Pol with
GST-UL44 (Figure 5A, lanes 8–12, and Figure 5B). Thus,thesis.
BP5 specifically inhibits the HSV Pol-UL42 interaction.
Specific Inhibition of Interaction of UL42
with Full-Length Pol BP5 Exhibits More Potent Antiviral
Than Cytotoxic ActivityAlthough both BP1 and BP5 had been shown to inhibit
the interaction of UL42 with the Pol-derived peptide, we Because of the considerable evidence that the interac-
tion between Pol and UL42 is required for viral replica-wished to determine if they could inhibit the interaction
of UL42 with full-length Pol by using a pull-down assay. tion, we investigated the antiviral effect of BP5 by using
two assays in Vero cells: plaque formation (Figure 6A),In this assay, full-length Pol was expressed as a radiola-
beled protein by using in vitro translation in reticulocyte which entails a low multiplity of infection, and yield (Fig-
ure 6B), which measures the amount of infectious viruslysates. When mixed with MBP-UL42, the radiolabeled
Pol (UL30) was retained on amylose columns that bind produced following a single cycle of viral replication
Table 1. Potencies of Selected Compounds in Biochemical Assays
IC50 (M) for:
Fluorescence Polarization Long Chain DNA DNA Synthesis
Compound (UL42 and Pol Peptide) Synthesis (Pol/UL42) by Pol Alone
Peptide A 5 2a 50a
BP1 35 25 100
BP3 12 30 25
BP5 15 26 100
BP9 48 25 25
a Data from [15].
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yield with an ED50 of 0.3 M. Similar results were ob-
tained with another HSV-1 strain (not shown).
In parallel, we tested the cytotoxicity of BP5 in Vero
cells by using an assay in which, in the presence of an
electron-coupling reagent, only viable cells convert a
compound (XTT) to a form that can be measured colori-
metrically. BP5 exhibited cytotoxicity in this assay (Fig-
ure 6C) but at concentrations substantially higher than
those at which it exhibited antiviral activity (IC5020M).
Thus, BP5 appears to exhibit selective anti-HSV activity.
Implications and Prospects
The primary goal of this study, which stems from previ-
ous work showing that interruption of a few hydrogenFigure 4. Effect of Compounds on Long-Chain DNA Synthesis by
bonds is sufficient to disrupt HSV polymerase subunitPol and UL42
interactions [8], was to identify a small molecule thatAssays were performed with a poly(dA) template and an oligo(dT)
can specifically inhibit these interactions in vitro. Fromprimer and labeled TTP. The reaction products were analyzed by
alkaline agarose electrophoresis and autoradiography. Lane 1, HSV a library of 16,000 molecules, we found a compound,
Pol alone; lanes 2–17 HSV Pol plus UL42 either without any added here termed BP5, that inhibits the binding of UL42 to
candidate inhibitor (lane 2), with 40 or 20 M peptide A (lanes 3 and both a Pol-derived peptide and full-length Pol, and inhib-
4, respectively), with 30 M BP1, BP2, BP3, BP4, BP5, BP6, BP7,
its the functional consequences of the Pol-UL42 interac-or BP8 (lanes 5–12, respectively), or with 100, 75, 50, 25, or 12 M
tion, long-chain DNA synthesis. This compound was notBP9 (lanes 13–17, respectively).
identified in a screen of the same library for inhibition
of another protein-protein interaction [20], it did not de-
tectably inhibit the binding of the subunits of a homolo-initiated at a high multiplicity of infection. BP5 inhibited
plaque formation by wild-type HSV-1 strain KOS with a gous herpesvirus polymerase, and it did not potently
inhibit the activity of HSV Pol alone. Thus, BP5 is a50% effective dose (ED50) of 2 M and inhibited virus
Figure 5. BP5 Inhibits the Interaction of Full-
Length HSV Pol and UL42
(A) Cell-free translated HSV Pol (lanes 1–6, 14)
or HCMV polymerase catalytic subunit (UL54,
lanes 7–13) were mixed with either MBP-UL42
(UL42, lanes 1–5), a GST fusion to the HCMV
homolog of UL42 (UL44, lanes 8–12, 14), or
with no protein (lanes 6 and 13), and the indi-
cated concentrations of BP5. The reactions
in lanes 1–7 were bound to and eluted from
an amylose column, and the reactions in
lanes 8–14 were bound to and eluted from
a gluathione column and analyzed by SDS
polyacrylamide gel electrophoresis and auto-
radiography.
(B) Autoradiographs such as those in (A) were
quantified by phosphorimager and the per-
centage of signal relative to that in the ab-
sence of BP5 was plotted versus BP5 con-
centration (HSV Pol/UL42, squares; HCMV
UL54/UL44, circles). The data shown are the
average of two experiments  the standard
error of the mean.
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indeed, due to its inhibition of polymerase subunit inter-
actions. Clearly, it could exert antiviral activity via any
number of other mechanisms. To investigate the mecha-
nism of antiviral action, we have recently isolated an HSV
mutant resistant to BP5 (C.C. and D.M.C., unpublished
results). This indicates that the compound acts via a
virus-specific mechanism. However, the mutant’s de-
gree of resistance is limited and our ability to analyze
the mechanism of resistance is made difficult by the
cytotoxicity of BP5 at higher concentrations. More po-
tent, less toxic derivatives of BP5 could aid this effort.
Regardless, BP5 is likely to provide a useful tool for
investigating the importance of Pol-UL42 interactions
during DNA synthesis in vitro and in infected cells. BP5
also represents an interesting starting point for the dis-
covery of drugs that may be more potent than ACV and
that should be active against viral mutants resistant to
currently existing drugs such as ACV.
Significance
Protein-protein interactions are crucial to most, if not
all, biological processes. Because these interactions
also often determine specificity, selective disruption of
these interactions should, in principle, be an excellent
Figure 6. Antiviral Activity and Cytotoxicity of BP5 strategy for drug discovery. However, there are only a
(A) The effect of BP5 on plaque formation in Vero cells by HSV-1 few examples of small molecules that disrupt protein-
strain KOS. protein interactions and exert effects inside cells. Such
(B) The effect of BP5 on the yield of KOS in Vero cells in single-
interactions could provide targets for new drugscycle growth assays.
against herpes simplex virus (HSV), which causes a(C) The effect of BP5 on Vero cell viability as measured by an XTT
spectrum of diseases that are especially severe inassay. The absorbances measured in the XTT assay were plotted
onto a standard curve of numbers of cells versus absorbance to newborns and immunosuppressed individuals, such
measure the number of viable cells remaining. as patients with AIDS. Although antivirals against HSV,
such as acyclovir (ACV), are widely used, new drugs
are needed, especially for combatting ACV-resistant
specific inhibitor of Pol-UL42 interactions in vitro and infections. A protein-protein interaction that has been
joins a short but expanding list of small molecules that characterized structurally and mutationally is that be-
can specifically abrogate protein-protein interactions tween the catalytic subunit UL30 (Pol) and the pro-
[1, 2]. To our knowledge, it is the first small molecule not cessivity subunit UL42 of the HSV DNA polymerase. It
derived from a peptide that interferes with interactions has been shown that individual Pol and UL42 residues
between viral proteins. are crucial for the interaction, suggesting that a small
We do not know whether BP5 binds to UL42 or to the molecule might be able to disrupt the interaction. We
C terminus of Pol, whether it inhibits competitively by therefore developed and validated a high-throughput
binding to the interaction interface, or whether it inhibits screen for compounds that could disrupt polymerase
allosterically. The mechanism of action of BP5 may be subunit interactions and applied it to a library of small
of interest in understanding inhibitors of protein-protein molecules. Among these, we have identified a mole-
cule that specifically inhibits Pol-UL42 interactions,interactions generally. Regardless of mechanism, the
both physically and functionally. To our knowledge,identification of BP5 proves the concept that HSV poly-
this is the first small molecule not derived from a pep-merase subunit interactions can be specifically dis-
tide that interferes with interactions between viral pro-rupted by a small molecule.
teins. Moreover, this molecule has antiviral activityBased on previous studies [9, 10, 12, 16], we predicted
that is more potent than its cytotoxic activity. Thisthat a small molecule that inhibits Pol-UL42 interactions
small molecule is likely to provide a useful tool forwould have antiviral activity. It was pleasing then to
investigations of the Pol-UL42 interaction and its roleobserve that BP5 exhibits more potent antiviral than
in viral DNA replication. It also represents an interest-cytotoxic activity. The potency of BP5 in our antiviral
ing starting point for the discovery of new anti-HSVassays was greater than in the in vitro assays. This may
drugs that should be active against viral mutants resis-reflect lower concentrations of polymerase subunits in
tant to currently existing drugs such as ACV.cells relative to those employed in the biochemical
assays. The antiviral potency of BP5 is in the same
Experimental Proceduresrange as that of ACV, but it is much more toxic. We are
presently attempting to identify more potent, less toxic Peptides and UL42
derivatives of BP5. Peptide A, corresponding to the 36 C-terminal amino acids of HSV
Pol [15], and a peptide comprising the 18 C-terminal amino acids ofWe do not know whether BP5’s antiviral activity is,
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HSV Pol that is N-terminally labeled with the pentafluorofluorescein- eluted with binding buffer containing 10 mM maltose or 15 mM
glutathione, respectively. The samples were then subjected to SDS-derivative Oregon Green 514 (Molecular Probes) were synthesized
and HPLC-purified by C. Dahl at the Biopolymers Facility of the polyacrylamide gel electrophoresis and autoradiography.
Department of Biological Chemistry and Molecular Pharmacology
(Harvard Medical School). Recombinant MBP-UL42 protein was ex- Assays of Antiviral Activity
pressed as a truncated form ending at residue 340 (C340) and Plaque reduction assays of the antiviral activity of BP5 in Vero (Afri-
purified by amylose column chromatography, as described [8]. For can green monkey kidney) cells were performed essentially as de-
assays of interaction with full-length Pol, the protein was additionally scribed [25] with the following modifications: virus was adsorbed
purified by ssDNA-agarose chromatography as described [8]. The in a volume of 1 ml for 2 hr. The inocula were then removed, and
protein was concentrated by using spin columns (BioRad, Centri- medium containing methylcellulose and various concentrations of
con) when necessary, and stored at 80C until further use. After BP5 was added. Plaques were counted after crystal violet staining
thawing, the purification buffer was exchanged to low fluorescent after 2 days. As a control, the concentration of DMSO corresponding
grade reagents (PanVera), and any maltose was removed simultane- to that present in the medium containing the highest concentration
ously by using 10-DG Bio-Gel columns (BioRad). of BP5 tested was assayed and found not to reduce plaque forma-
tion. Yield reduction assays were perfomed at 37C in 24-well plates
FP Assays that were seeded with 1.5  105 Vero cells in 0.75 ml medium 1 day
1 nM of Oregon Green-labeled peptide was added to 7 M MBP- before infection. The medium was removed and inoculated with
UL42C340 in 50 mM TrisHCl (pH 7.5), 1 mM DTT, 0.5 mM EDTA, HSV-1 strain KOS at a multiplicity of infection of 5 plaque-forming
150 mM NaCl, 4% Glycerol and 100 g ml1 bovine 	 globulin and units/cell in 0.2 ml medium. Following adsorption for 2 hr, the inocu-
kept on ice until the mix was distributed into black 384-well plates lum was removed, the cells were rinsed with medium, and then
(LJL Biosystems) in a total volume of 20 l per well. All chemicals 0.2 ml medium containing various concentrations of BP5 or DMSO
were low fluorescent grade (PanVera). Small molecules (5 mg/ml in (which had no effect) was added. After 24 hr incubation, the plates
DMSO; ChemBridge) were obtained from the Harvard Institute of were frozen and thawed twice, and the infectious virus present in
Chemistry and Cell Biology (ICCB, Harvard Medical School), and 40 each well was titrated by plaque assay.
nl of each compound was transfered to individual wells using 384-
pin arrays (Genetix). To ensure comparable data, internal reference Assay of Cytotoxic Activity
values (peptide only, no compound, no DMSO) were included on Vero cells were seeded at 5  104 cells per well into 96-well plates
each screening plate. After incubation between 5 and 45 min at and treated with various concentrations of BP5 for 24 hr. in quadru-
room temperature, the FP values were determined by using an Ana- plicate. Cell viability was then determined with an XTT assay (Roche
lyst plate reader (LJL Biosystems) at the ICCB. Small molecules for Molecular Biochemicals) according to the manufacturer’s protocol
further testing were obtained from ChemBridge. by using a Victor plate reader (Wallac).
DNA Polymerase Assays Supplemental Data
Selected compounds were tested for their ability to inhibit either the Supplemental Data including three figures are available at http://
activity of Pol alone by using an oligo(dT) primer (Roche Molecular www.chembiol.com/cgi/content/full/11/5/647/DC1/.
Biochemicals) and a poly(dA) template (Amersham Pharmacia) or
UL42-mediated long-chain DNA synthesis by Pol [14, 15, 21] on the
Acknowledgmentssame primer-template. Reaction mixtures (50 mM TrisHCl [pH 7.5],
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